| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 08/23/2001 | CA2400862A1 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors |
| 08/23/2001 | CA2400860A1 Aminoalcohol derivatives |
| 08/23/2001 | CA2400634A1 Genetic modification of the lung as a portal for gene delivery |
| 08/23/2001 | CA2400619A1 Purine derivatives |
| 08/23/2001 | CA2400588A1 Peptide and nucleic acid coding therefor for the detection, diagnosis and therapy of diseases of the nervous system |
| 08/23/2001 | CA2400374A1 Oral, nasal and pulmonary dosage formualtions of copolymer 1 |
| 08/23/2001 | CA2400360A1 Polypeptides and nucleic acids encoding same |
| 08/23/2001 | CA2400353A1 Method for reducing or eliminating smoking |
| 08/23/2001 | CA2400332A1 Polypeptides and nucleic acids encoding same |
| 08/23/2001 | CA2400256A1 Compositions useful for regulating parkin gene activity |
| 08/23/2001 | CA2400021A1 Aryloxyacetic acids for diabetes and lipid disorders |
| 08/23/2001 | CA2399147A1 4-imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use as alpha-1a agonists |
| 08/23/2001 | CA2398937A1 Substituted arylpyrazines |
| 08/23/2001 | CA2398706A1 Cytoprotective steroids (ii) |
| 08/23/2001 | CA2397651A1 Amine derivatives for the treatment of apoptosis |
| 08/23/2001 | CA2397560A1 Use of paullone derivatives for making medicines |
| 08/23/2001 | CA2397233A1 Biarylcarboxamides |
| 08/23/2001 | CA2396793A1 Uses of agonists and antagonists to modulate activity of tnf-related molecules |
| 08/23/2001 | CA2395862A1 Succinoylamino carbocycles and heterocycles as inhibitors of a.beta. protein production |
| 08/23/2001 | CA2395854A1 Nucleoside analogs with carboxamidine-modified bicyclic base |
| 08/22/2001 | EP1126027A1 Cell death inhibition by the caspase-12 activation inhibitor MAGE-3 |
| 08/22/2001 | EP1125942A1 Derivatives of 6-amino or 6-hydrazinosulfonyl-3-quinolyl phosphonic acids, process for their preparation and pharmaceutical compositions containing them |
| 08/22/2001 | EP1125941A1 Derivatives of 6-sulfamoyl-3-quinolyl phosphonic acids, process for their preparation and pharmaceutical compositions containing them |
| 08/22/2001 | EP1125940A1 Derivatives of aryl or heteroaryl quinolinylphosphonic acids, process for their preparation and pharmaceutical compositions containing them |
| 08/22/2001 | EP1125938A1 Protein kinase inhibitors for treatment of neurological disorders |
| 08/22/2001 | EP1125925A1 Amine derivatives for the treatment of apoptosis |
| 08/22/2001 | EP1125581A1 Use of sertraline to treat panic disorder |
| 08/22/2001 | EP1125579A2 Uses of agrp-melanocortin receptor binding modulating compounds |
| 08/22/2001 | EP1125135A2 A complex of a chaperone with -amyloid and methods employing this complex |
| 08/22/2001 | EP1124980A2 Method for the production of quercetin and isoquercetin derivatives |
| 08/22/2001 | EP1124959A1 Cell surface molecule-induced macrophage activation |
| 08/22/2001 | EP1124951A2 Human sorting nexins |
| 08/22/2001 | EP1124850A1 12 human secreted proteins |
| 08/22/2001 | EP1124848A2 Transmembrane 4 proteins |
| 08/22/2001 | EP1124846A2 Nucleotide and protein sequences of nogo genes and methods based thereon |
| 08/22/2001 | EP1124845A2 Phosphinate peptide analogs for the treatment of fibrotic disorders |
| 08/22/2001 | EP1124828A1 Pyrano, piperidino, and thiopyrano compounds and methods of use |
| 08/22/2001 | EP1124814A1 Aromatic derivatives and iron complexes thereof for the use as normalising agents of the iron level |
| 08/22/2001 | EP1124811A1 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| 08/22/2001 | EP1124810A1 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| 08/22/2001 | EP1124809A1 Benzoylpyridazines |
| 08/22/2001 | EP1124806A2 Use of n-substituted (3,6-dihydro)-2h-1,2-oxazine derivatives as selective mglur1 antagonists |
| 08/22/2001 | EP1124804A1 Prostaglandin endoperoxide h synthase biosynthesis inhibitors |
| 08/22/2001 | EP1124801A1 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress |
| 08/22/2001 | EP1124794A1 Substituted 3,3-diamino-2-propenenitriles, their preparation and use |
| 08/22/2001 | EP1124577A1 USE OF AN ENTEROBACTERIUM PROTEIN OmpA FOR SPECIFIC TARGETING TOWARDS ANTIGEN-PRESENTING CELLS |
| 08/22/2001 | EP1124559A1 Compositions for the treatment and prevention of neurological and pathopsychological diseases |
| 08/22/2001 | EP1124556A1 Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders and composition thereof |
| 08/22/2001 | EP1124555A1 Method of treating neurodegenerative diseases |
| 08/22/2001 | EP1124551A2 Delta 9 tetrahydrocannabinol (delta 9 thc) solution metered dose inhalers and methods of use |
| 08/22/2001 | EP0785926B1 Carboxylic acid derivatives, their preparation and their use as medicaments |
| 08/22/2001 | EP0777653B1 Dihygropyridine derivatives as bradykinin antagonists |
| 08/22/2001 | EP0752854B1 Pyrimidine or triazine carboxylic acid derivatives to be used as medicaments |
| 08/22/2001 | EP0626851B1 Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine for the preparation of a medicament for the treatment of certain types of pain and of oedema |
| 08/22/2001 | CN1309657A Use of diazepins for preparing medicines for treating pathological conditions or diseases involving one of growth hormone release inhibiting factor receptors |
| 08/22/2001 | CN1309654A Biphenyl derivs. |
| 08/22/2001 | CN1309642A Novel 1,2,5-trisubstd. 1,2-dihydro-indazol-3-ones with anti-asthmatic, anti-allergic, anti-inflammatory, immuno-modulating and neuro-protective effects, method for production and use as medicam ent |
| 08/22/2001 | CN1309641A Quinoline derivs. |
| 08/22/2001 | CN1309640A Quinoline derivs. |
| 08/22/2001 | CN1309638A N-substd. naphthalene carboxamides as neurokinin-receptor antagonists |
| 08/22/2001 | CN1309631A Aminomethylcarboxylic acid derivs |
| 08/22/2001 | CN1309564A Method of treatment |
| 08/22/2001 | CN1309563A Use of 1-(aminoalkyl)-3-quinoxaline-2-one derives for preparation of compounds having antioxidant action |
| 08/22/2001 | CN1309562A Topical compositions comprising opioid analgesic and NMDA antagonist |
| 08/22/2001 | CN1309560A Prevention of migraine recurrence |
| 08/22/2001 | CN1309558A Transdermal patch and topical compositions comprising propylnorapomorphine |
| 08/22/2001 | CN1309557A Formulation contg. paroxetine |
| 08/22/2001 | CN1309127A Piperazidine deriv. and preparing method thereof |
| 08/22/2001 | CN1308959A Medicine 'Yishenjieyu' for treating mental diseases (psychosis) |
| 08/22/2001 | CN1308958A Medicine 'Huoxuexingshen' for treating mental diseases (psychosis) |
| 08/22/2001 | CN1308952A Chinese medicine for treating trigeminal neuraligia and its preparing process |
| 08/22/2001 | CN1308947A Drug-dropping tea and its preparing process |
| 08/22/2001 | CN1308938A Antalgic and sedative oral etomidate preparation |
| 08/21/2001 | US6277987 Sulfonylamino acid and sulfonylamino hydroxamic acid derivatives |
| 08/21/2001 | US6277979 KIAA0551 polynucleotides and polypeptides use |
| 08/21/2001 | US6277977 cDNA clone HAPOI67 that encodes a human 7-transmembrane receptor |
| 08/21/2001 | US6277960 Amino acid sequence of g protein coupled receptor; treatment of eating disorders, asthma, parkinson's disease, cardiovascular and nervous system disorders, huntington's disease, tourett's syndrome, and others; diagnosis |
| 08/21/2001 | US6277887 Methods for treating Parkinson's disease using optically pure (−)-bupropion |
| 08/21/2001 | US6277886 Pharmaceutical compositions comprising S-(−)-N-propargyl-1-aminoindan |
| 08/21/2001 | US6277878 Substituted indole compounds as anti-inflammatory and analgesic agents |
| 08/21/2001 | US6277876 Antiinflammatory agents; prevent tissue degradation |
| 08/21/2001 | US6277875 Use of dopamine D2/D3 receptor agonists to treat fibromyalgia |
| 08/21/2001 | US6277872 Antiischemic agents; brain disorders |
| 08/21/2001 | US6277870 Use |
| 08/21/2001 | US6277866 Alzheimer's disease |
| 08/21/2001 | US6277864 Use of R- +)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders |
| 08/21/2001 | US6277861 For treatment and prophylaxis of nervous system disorders, psychological disorders, muscular disorders, drug addiction withdrawal, pain |
| 08/21/2001 | US6277853 Indole derivatives as 5-HT1B and 5-HT1D agonists |
| 08/21/2001 | US6277852 Piperazinyl 5-HT1 agonists and antagonists |
| 08/21/2001 | US6277839 Antiinflammatory agents, antipyretics, analgesics; side effect reduction |
| 08/21/2001 | US6277828 Aqueous isotonic solutions containing human serum albumin, sodium chloride and citric acid, suitable for lyophilization, useful for the treatment of alzheimer's disease |
| 08/21/2001 | US6277824 Enhancing or inhibiting cadherin-mediated functions comprising a his-ala-val sequence binding motif, an peptidomimetic or an antibody that binds to such a motif |
| 08/21/2001 | US6277594 Neurogenesis inducing gene |
| 08/21/2001 | US6277593 Generating preferential polypeptide; culture transformed cells, express preferential polypeptide, recover preferential polypeptide |
| 08/21/2001 | US6277585 Vertebrate unc-5 proteins which function as receptor proteins for netrins, a family of cell guidance proteins; use in diagnosis, therapy and in the biopharmaceutical industry |
| 08/21/2001 | US6277398 Analgesic drug composition containing a capsaicinoid and potentiator therefor |
| 08/21/2001 | US6277393 Systemic and/or local (topical) application of tetracycline and/or tetracycline derivative(s) for treating, suppressing and preventing of cerebrovascular diseases, traumas and damages of nervous system |
| 08/21/2001 | US6277384 The amount of opioid antagonist included in the combination product provides at least a mildly negative, ?aversive? experience in physically dependent addicts (e.g., precipitated abstinence syndrome). |
| 08/21/2001 | US6277373 Phosphatidylinositol 4,5-bisphosphate 5-phosphatase |
| 08/21/2001 | US6277372 Porcine ventral mesencephalic cells obtained from an embryonic pig of between ages 24 and 30 of gestation from embryonic connective tissue; |